- Home
- ALMS vs CELC Comparison
ALMS vs CELC Comparison
Compare ALMS & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALMS
- CELC
- Stock Information
- Founded
- ALMS 2021
- CELC 2011
- Country
- ALMS United States
- CELC United States
- Employees
- ALMS N/A
- CELC N/A
- Industry
- ALMS
- CELC Medical Specialities
- Sector
- ALMS
- CELC Health Care
- Exchange
- ALMS NYSE
- CELC Nasdaq
- Market Cap
- ALMS 402.6M
- CELC 327.3M
- IPO Year
- ALMS 2024
- CELC 2017
- Fundamental
- Price
- ALMS $5.00
- CELC $10.24
- Analyst Decision
- ALMS Strong Buy
- CELC Strong Buy
- Analyst Count
- ALMS 7
- CELC 6
- Target Price
- ALMS $28.17
- CELC $30.17
- AVG Volume (30 Days)
- ALMS 1.6M
- CELC 392.7K
- Earning Date
- ALMS 05-15-2025
- CELC 05-14-2025
- Dividend Yield
- ALMS N/A
- CELC N/A
- EPS Growth
- ALMS N/A
- CELC N/A
- EPS
- ALMS N/A
- CELC N/A
- Revenue
- ALMS N/A
- CELC N/A
- Revenue This Year
- ALMS N/A
- CELC N/A
- Revenue Next Year
- ALMS N/A
- CELC N/A
- P/E Ratio
- ALMS N/A
- CELC N/A
- Revenue Growth
- ALMS N/A
- CELC N/A
- 52 Week Low
- ALMS $3.18
- CELC $7.58
- 52 Week High
- ALMS $13.53
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- ALMS N/A
- CELC 54.38
- Support Level
- ALMS N/A
- CELC $7.58
- Resistance Level
- ALMS N/A
- CELC $10.48
- Average True Range (ATR)
- ALMS 0.00
- CELC 1.04
- MACD
- ALMS 0.00
- CELC 0.17
- Stochastic Oscillator
- ALMS 0.00
- CELC 80.01
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.